Moleculin Biotech, Inc. MBRX 深 沪
等待开盘 05-21 09:30:00 美东时间
2.37
+0.020
+0.85%
华盛通- 最 高2.37
- 今 开2.36
- 成交量 4.96万股
- 最 低 2.28
- 昨 收 2.35
- 总市值 1264.71万
- 52周最高 24.00
- 市盈率 静 --
- 换手率 0.93%
- 52周最低 1.79
- 委 比 50.00%
- 总股本 533.64万
- 历史最高 21555.00
- 量 比 0.16
- 振 幅 3.83%
- 历史最低 1.79
- 每 手 1
- 风险率 6.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses of $(15.80) per share
05-15 21:20
Moleculin Biotech Announces Significant Advancement In IP Portfolio With Issuance Of Hong Kong Patent Covering Proprietary Method Of Reconstituting Liposomal Annamycin
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseHOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today
05-08 20:47
Moleculin Biotech secures Hong Kong patent for liposomal Annamycin reconstitution method
Moleculin Biotech secures Hong Kong patent for liposomal Annamycin reconstitution method Moleculin Biotech won a Hong Kong patent covering its method of reconstituting liposomal Annamycin, extending protection through June 25, 2040. Patent, No. 40073244, is jointly owned with University of Texas Sys
05-08 20:45
Moleculin Highlights Promising Preclinical Data for L-ANN
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On April 23, 2026, Mo...
04-23 20:51
Moleculin to present annamycin cardiac safety pooled analysis at ASCO 2026
Moleculin to present annamycin cardiac safety pooled analysis at ASCO 2026 Moleculin Biotech disclosed acceptance of an abstract on its lead drug candidate annamycin for poster presentation at 2026 ASCO Annual Meeting. Data will be presented May 30, 2026, in Chicago. Poster reports pooled analysis i
04-21 20:36
Moleculin Biotech Stockholders Approve Warrant Share Issuance
Moleculin Biotech ( ($MBRX) ) has shared an update. At a special meeting of sto...
04-15 23:59
Scalable Biotech Manufacturing Unlocks a $14B Market
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflecti...
03-27 21:15
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Moleculin Biotech reports FY results
Moleculin Biotech press release (MBRX): FY EPS of -$28.42. As of December 31, 2025, the Company had cash and cash equivalents of $8.9 million and prepaid expenses and other current assets of $0.8 mill...
03-20 02:59
Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over losses of $(9.25) per
03-19 21:38
